Low Dose Rivaroxaban Plus Aspirin Reduces Major Adverse Limb Events in COMPASS A COMPASS subgroup analysis

According to a new subgroup analysis of the COMPASS trial published in the Journal of the American College of Cardiology, the prevention of Major Adverse Limb Events (MALE) is of utmost importance in patients with lower extremity Peripheral Arterial Disease (PAD) due to its poor prognosis. Additionally, it has been found that the aspirin and rivaroxaban 2.5mg twice daily combination leads to a significant reduction of Major Adverse Limb Events (MALE) in these patients.

Continue reading

SCAI Peripheral Vascular Disease Device Selection Dr. Dmitriy Feldman and Dr. C. Michael Gibson Discuss

Prevention of Cardiovascular Events in PAD and the Role of Anticoagulation

Dr. Sonia Anand Speaks at Brigham and Women’s Hospital

Prevention of CV Events in PAD & Role of Anticoagulation Dr. Sonia Anand Speaks at Brigham and Women's Hospital

EAGLES- A Randomized Clinical Trial Showing No Evidence of Smoking Cessation Treatments Association with MACE

EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a randomized clinical trial, published in the Journal of the American Medical Association, provides evidence that smoking cessation medications do not increase the risk of serious cardiovascular events in the general population of smokers. Continue reading

Preventing Heart Attack, Stroke, and Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease

Dr. John Eikelboom Speaks at Brigham and Women’s Hospital

Preventing Heart Attack, Stroke, and Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease Dr. John Eikelboom Speaks at Brigham and Women's Hospital

Critical Limb Ischemia: Overview and Unmet Needs Dr. Duane Pinto, Dr. Eric Secemsky & Dr. C. Michael Gibson Discuss

Critical Limb Ischemia: Overview and Unmet Needs

Dr. Duane Pinto, Dr. Eric Secemsky & Dr. C. Michael Gibson Discuss

Subscribe on iTunes or Google Play.

Origins and future of the PE response team Dr. Kenneth Rosenfield and Dr. C. Michael Gibson Discuss

Evolocumab and Outcomes in Patients with PAD Dr. Marc Bonaca and Dr. C. Michael Gibson Discuss

GM-CSF with and without Supervised Exercise in PAD Dr. Mary McDermott and Dr. C. Michael Gibson Discuss

GM- CSF and Supervised Exercise in PAD

Dr. C. Michael Gibson discusses the trial findings with Dr. Mary McDermott at AHA 2017.

Origins and Future of the PE Response Team

Dr. Kenneth Rosenfield and Dr. C. Michael Gibson Discuss